A2 Biotherapeutics is pioneering innovative treatments for solid tumors through its proprietary Tmod™ platform, which precisely distinguishes tumor cells from normal cells. This first-mover advantage allows A2 Bio to develop a broad pipeline of T cell therapies, leveraging both autologous and allogeneic approaches. The company is well-positioned in the biotechnology sector, supported by a seasoned management team with over 90 years of combined experience. A2 Bio's commitment to rigorous science and its in-house cGMP manufacturing capabilities enhance its market position and traction in the competitive landscape of cancer treatment.

Alector is pioneering the development of novel therapeutics for neurodegenerative diseases by leveraging insights from immunology, neuroscience, and human genetics. Their innovative approach, termed immuno-neurology, aims to harness the brain's immune system to combat conditions such as Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis. With a robust pipeline of therapeutic candidates, Alector is focused on transforming the treatment landscape for these debilitating diseases, aiming to improve the lives of millions affected by neurodegeneration. Their commitment to scientific excellence and a culture of curiosity positions them as a leader in the biotechnology sector, with significant potential for impactful advancements in patient care.

Alt Pep is a biomedical startup focused on transforming the diagnosis and treatment of amyloid diseases, including Alzheimer’s and Parkinson’s. Their innovative platform utilizes custom-designed synthetic peptides to selectively target and neutralize toxic oligomers associated with these diseases, enabling early detection and intervention. With a strong emphasis on scientific research and development, Alt Pep aims to make significant breakthroughs that could impact over a billion people globally, positioning itself as a leader in the biotech space.

Arbor Biotechnologies is pioneering next-generation gene editing to revolutionize the treatment of genetic diseases. The company focuses on discovering and developing genomic medicines that address the root causes of these diseases, utilizing a diverse toolbox of novel gene editors. With a commitment to curing all patients suffering from genetic conditions, Arbor is positioned at the forefront of the biotech industry, leveraging advanced technologies to rewrite the human genome and provide functional cures.

Arc is a venture-backed startup electrifying the marine industry and is headquartered in Los Angeles, California. Led by a team of former rocket engineers, we’re developing, manufacturing, and delivering high-performance electric boats at lightning speed. Our groundbreaking first model, the Arc One, set a new industry standard as the most powerful electric boat commercially available at launch. And, it was just the beginning. Our second model, the Arc Sport, is delivering electric boating to the mass market. We’re continuing to chart new waters with future models until everything that floats is electric.

Aspen Neuroscience is a private biotechnology company focused on developing the first autologous neuron replacement therapies for Parkinson's disease. Utilizing stem cell biology and genomics, the company aims to provide personalized cell therapies that restore neuronal function and modify disease progression. Founded in 2018, Aspen is advancing its lead product, ANPD001, and is backed by a strong scientific team from The Scripps Research Institute. The company is committed to innovation and collaboration, positioning itself as a leader in addressing high unmet medical needs in neurodegenerative diseases.

Autobahn therapeutics is focused on improving life health for people affected by cns disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. Cns drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at autobahn to make a real difference in the lives of people.

Avitide has pioneered a new generation of affinity purification solutions for the biopharmaceutical manufacturing industry, offering AVIPure™ affinity resins that enable efficient processing for a wide range of drug modalities. The company addresses bioprocessing challenges by developing proprietary solutions that improve process economics and the manufacture of next-generation biotherapeutics. With a focus on flexibility, scalability, and quality, Avitide's ISO 9001:2015 certified operations support diverse clinical and commercial supply demands. The company has impacted over 250 million potential patients worldwide, establishing itself as a leader in biopharmaceutical affinity purification with a commitment to innovation and long-term value for its partners.

Basecamp Research is dedicated to tackling the toughest challenges in life sciences by pushing the boundaries of known biology. With the world’s largest biological database, we give AI a complete understanding of the true breadth and complexity of biology. This allows us to design complete biological systems with controllability, novelty and performance that far exceeds the previous state of the art. Today, our partners include trail-blazing labs and several of the top 10 biopharma companies. Our unique knowledge graph is driving breakthrough performance – going far beyond previous speed and complexity limits, and we are proud to partner with biodiversity partners across the globe, building a foundational database tailored to AI.

Bash is a productivity tool designed to streamline workflows by automating meeting follow-ups, project documentation, and industry research. It integrates AI to help users capture key takeaways from meetings, create project documents quickly, and track industry trends. With a focus on reducing information overload, Bash offers a suite of tools including meeting recorders, document generators, and competitive intelligence features. The platform is built by a team with experience at Google and Uber, aiming to enhance productivity and collaboration across various teams such as marketing, product, HR, and sales. Bash's freemium model allows users to access essential features for free while offering paid plans for more extensive use, making it accessible for teams of all sizes.

Big Hat Biosciences is a Series B biotech company based outside San Francisco that leverages machine learning and synthetic biology to design safer and more effective antibody therapies. Their Milliner platform integrates a high-speed wet lab with advanced machine learning technologies, enabling the rapid synthesis, purification, and characterization of hundreds of recombinant antibodies weekly. With a pipeline of wholly-owned and partnered therapeutic programs, Big Hat has raised over $100 million from top investors and is recognized for its innovative approach to tackling complex diseases through next-generation antibody therapies.

Bloom Text is a secure, HIPAA-compliant texting platform designed for healthcare organizations, enabling effortless communication with patients, clients, and staff. The platform streamlines communication workflows, enhances patient experience, and allows for secure messaging without requiring recipients to download an app. With features like document scanning, team messaging, and broadcast SMS, Bloom Text supports over 15,000 users and 2,840 organizations, sending 7 million messages and facilitating 22,000 video calls. Its differentiation lies in its focus on healthcare, making it a trusted choice for professionals looking to improve operational efficiency and patient satisfaction.